Enzon' HIF-1 Alpha Antagonist Study Shows Signs Of Clinical Benefit
Enzon Pharmaceuticals has announced the data from its HIF-1 alpha Phase 1 study evaluating EZN-2968 in patients with solid tumors and lymphoma. Study results demonstrated that the compound is well tolerated, and that early signs of clinical benefit, prolonged stable disease, were observed.
EZN-2968 is the first clinical product candidate to target the HIF-1 transcription factor. HIF-1 regulates expression of many key genes important in cancer biology.
Jeffrey Buchalter, Enzon’s Chairman and CEO, said: “We have yet to see a dose limiting toxicity and we continue to be encouraged by the early clinical signals in this program.”
“The duration of clinical benefit in certain histologies has exceeded our expectations at this phase of development. We look forward to advancing this promising compound into Phase II trials later this year, once a dose is determined,” he added.
Related Insight
Suppliers Directory
Kuecept - Concept Formulation Design
Kuecept Ltd is a specialist pharmaceutical contract research organisation supporting clients with the early phase development of low solubility, poorly bioavailable compounds. Our patented drug delivery technologies and formulation expertise in oral and parenteral dosage form design and development are used to fast track compounds through preclinical efficacy studies and toxicity testing and into clinic with robust, stable and improved performance products.
Suppliers
Mission3 - See Your Regulatory World in a New Light
Mission3 is the leading regulatory information management software provider for the worldwide life science industry, with offices in the US and Europe.
Suppliers
Avery Dennison - Innovative Pharmaceutical Label Materials for Identification, Security and More
The Avery Dennison Corporation is a Fortune 500 company, specialising in the development and supply of an innovative range of self-adhesive labelling solutions for many markets, including the pharmaceutical segment.
Suppliers
SYSTAG – Laboratory Automation, Scale-up, Thermal Process Safety and Pilot Plant Control From a Single Hand
SYSTAG, System Technik AG is a global provider for lab automation and solutions in the chemical and pharmaceutical industry specialising in integrated automation projects, from development to pilot plant and process control, including thermal process analysing for a safe process design.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Contamination Concerns
Published by Phage Consultants
White Papers
Internet usage of Indian General Practitioners
Published by Kinapse
White Papers
Biomarker Solutions
Published by Randox
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.